The Can-SAD Study: A Randomized Controlled Trial of the Effectiveness of Light Therapy and Fluoxetine in Patients With Winter Seasonal Affective Disorder

This study directly compared two common treatments for winter Seasonal Affective Disorder (SAD):

1. Bright Light Therapy: Specifically, 10,000-lux white fluorescent light administered for 30 minutes each morning.
2. Antidepressant Medication: Fluoxetine (commonly known as Prozac), at a dose of 20 mg per day.

The study used two comparator conditions to maintain blinding:

• For the light therapy group, participants received 10,000-lux light treatment along with a placebo capsule (an inactive pill designed to look identical to fluoxetine).
• For the fluoxetine group, participants received 20 mg/day of fluoxetine along with a placebo light (a 100-lux light treatment, which is too dim to be therapeutic for SAD, designed to mimic the experience of using a light box without providing active treatment).

The primary outcome measure was the overall improvement in depressive symptoms associated with SAD. Secondary outcomes included clinical response rates, remission rates, and the occurrence of adverse events (side effects).

The study included a total of 96 patients who were randomly assigned to one of the two treatment conditions. These individuals were recruited from four different Canadian centers and participated in the study over three consecutive winter seasons.

To be eligible, participants had to meet specific diagnostic criteria:

• They were diagnosed with Major Depressive Disorder with a seasonal (winter) pattern according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria. This means their depressive episodes consistently occurred during the winter months and remitted in the spring/summer.
• They had to have a baseline score of 23 or higher on the 24-item Hamilton Depression Rating Scale (HDRS-24). This score indicates at least moderate to severe depression, ensuring that only individuals with significant depressive symptoms were included.

The study focused exclusively on adults experiencing winter SAD, which means the findings are most directly applicable to this specific population.

The primary method for measuring the severity of depression and tracking improvement was the 24-item Hamilton Depression Rating Scale (HDRS-24).

• The HDRS-24 is a widely used, clinician-rated scale designed to assess the severity of depressive symptoms. A trained clinician interviews the patient and rates them on various items, including mood, guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, and more.
• Scores on the HDRS-24 typically range from 0 to 76, with higher scores indicating more severe depression. A score of 23 or higher was required for entry into this study, indicating moderate to severe depression.
• Changes in HDRS scores over the 8-week treatment period were used to determine overall improvement.
• Clinical response was defined as a 50% or greater reduction from the baseline HDRS score.
• Remission was defined as achieving a final HDRS score below a certain threshold (typically <7 or <10, though the exact threshold isn't specified in the abstract, it generally indicates minimal or no depressive symptoms).

Adverse events (side effects) were also monitored and reported, likely through patient self-report and clinician observation during follow-up visits.

This study employed a double-blind, randomized, controlled trial (RCT) design, which is considered the gold standard for evaluating the effectiveness of interventions. It was conducted across four Canadian centers over three winter seasons to capture the seasonal nature of SAD.

Study Design and Randomization: After an initial "baseline observation week" where participants' symptoms were assessed without active treatment, eligible patients were randomly assigned to one of two treatment groups. Randomization is crucial because it helps ensure that, on average, the two groups are similar in all characteristics (known and unknown) at the start of the study. This minimizes the risk that any observed differences in outcomes are due to pre-existing differences between the groups rather than the treatments themselves.

The two groups were:

1. Active Light Therapy Group: Received 10,000-lux white fluorescent light treatment for 30 minutes each morning, combined with a placebo capsule.
2. Fluoxetine Group: Received 20 mg/day of fluoxetine, combined with a 100-lux light treatment (the "placebo light").

Blinding: The study was double-blind, meaning neither the participants nor the researchers/clinicians assessing the outcomes knew which treatment each participant was receiving.

• Blinding for medication: This was achieved by using identical-looking capsules for both active fluoxetine and the placebo.
• Blinding for light therapy: This was more challenging but was addressed by using two types of light boxes. The active light box delivered 10,000 lux, while the placebo light box delivered only 100 lux. The placebo light box used neutral density filters to reduce the light intensity without altering its appearance significantly, making it difficult for participants to discern if they were receiving active or placebo light. This dual-blinding strategy (placebo capsule for the light group, placebo light for the fluoxetine group) was essential to minimize bias from patient expectations (placebo effect) and researcher observation (observer bias).

Duration: The active treatment phase lasted for 8 weeks, following the initial baseline observation week. This duration is common in antidepressant trials and allows sufficient time for treatments to take effect and for initial symptom improvement to stabilize.

Statistical Approach: The primary analysis used an intent-to-treat (ITT) approach. This means that all patients who were randomized were included in the analysis, regardless of whether they completed the full 8 weeks of treatment or adhered perfectly to their assigned intervention. ITT analysis is a robust method that provides a more realistic estimate of treatment effectiveness in real-world settings, as it accounts for dropouts and non-adherence, which are common in clinical practice. The study looked for overall improvement over time and differences between the treatment groups. Post hoc testing was also performed to explore differences at specific time points.

What this design can and cannot prove:

• What it can prove: As a double-blind, randomized controlled trial, this study design is excellent for establishing a causal relationship between the interventions and the observed outcomes. It can confidently state whether bright light therapy is as effective as fluoxetine for SAD, and which might have a better side effect profile. The double-blinding minimizes bias from both patient expectations and assessor knowledge, strengthening the internal validity of the findings. The ITT analysis provides a more conservative and generalizable estimate of effectiveness.
• What it cannot prove: A key limitation acknowledged by the authors is the lack of a "double-placebo" condition. This would have involved a group receiving both a placebo capsule and a placebo light (e.g., 100-lux light). Without this group, the study cannot definitively prove that either light therapy or fluoxetine is superior to a completely inert placebo. Instead, it primarily compares the relative effectiveness of light therapy versus fluoxetine. While both treatments showed improvement, we cannot conclude from this study alone how much of that improvement is due to the active treatment versus a general placebo effect or natural remission.

Major Methodological Weaknesses: The primary methodological weakness, as noted by the authors, is the absence of a true double-placebo control group. This means the study can compare the two active treatments against each other, but it cannot isolate the specific effect size of each treatment above and beyond the placebo effect. While both treatments showed improvement, it's impossible to quantify how much of that improvement was due to the active components versus the expectation of treatment or the structured care received. This limits the ability to make definitive statements about the absolute efficacy of either treatment compared to doing nothing at all.

The study's intent-to-treat analysis revealed several important findings regarding the comparison of 10,000-lux light therapy and 20 mg/day fluoxetine for winter SAD:

• Overall Improvement: Both treatment groups showed overall improvement with time in their depressive symptoms. This indicates that participants in both the active light therapy group and the fluoxetine group experienced a reduction in their SAD symptoms over the 8-week study period.
• No Difference in Overall Effectiveness: There were no significant differences between the two treatments in terms of overall symptom improvement over the 8 weeks. This suggests that, by the end of the study, light therapy was as effective as fluoxetine in reducing depression severity.
• Clinical Response Rates: The